Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Immutep Expands Part B of TACTI-002 Study

americanpharmaceuticalreviewMarch 10, 2021

Tag: Immutep , TACTI-002 , NSCLC , PD-L1

PharmaSources Customer Service